$4.80
6.67% today
Nasdaq, Apr 02, 10:00 pm CET
ISIN
US9842411095
Symbol
YMAB
Sector
Industry

Y-mAbs Therapeutics, Inc. Stock price

$4.50
-0.69 13.29% 1M
-8.71 65.93% 6M
-3.33 42.53% YTD
-11.69 72.21% 1Y
-8.56 65.54% 3Y
-20.25 81.82% 5Y
-19.50 81.25% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
+0.07 1.58%
ISIN
US9842411095
Symbol
YMAB
Sector
Industry

Key metrics

Market capitalization $203.48m
Enterprise Value $137.07m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.56
P/S ratio (TTM) P/S ratio 2.32
P/B ratio (TTM) P/B ratio 2.20
Revenue growth (TTM) Revenue growth 3.38%
Revenue (TTM) Revenue $87.69m
EBIT (operating result TTM) EBIT $-31.20m
Free Cash Flow (TTM) Free Cash Flow $-15.71m
Cash position $67.23m
EPS (TTM) EPS $-0.67
P/E forward negative
P/S forward 2.41
EV/Sales forward 1.62
Short interest 11.75%
Show more

Is Y-mAbs Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Y-mAbs Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Y-mAbs Therapeutics, Inc. forecast:

10x Buy
83%
1x Hold
8%
1x Sell
8%

Analyst Opinions

12 Analysts have issued a Y-mAbs Therapeutics, Inc. forecast:

Buy
83%
Hold
8%
Sell
8%

Financial data from Y-mAbs Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
88 88
3% 3%
100%
- Direct Costs 15 15
32% 32%
17%
73 73
1% 1%
83%
- Selling and Administrative Expenses 54 54
23% 23%
62%
- Research and Development Expense 49 49
10% 10%
56%
-31 -31
23% 23%
-35%
- Depreciation and Amortization 0.54 0.54
27% 27%
1%
EBIT (Operating Income) EBIT -31 -31
22% 22%
-36%
Net Profit -30 -30
38% 38%
-34%

In millions USD.

Don't miss a Thing! We will send you all news about Y-mAbs Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Y-mAbs Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
29 days ago
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Courtney Dugan - Head-IR Michael Rossi - President & CEO Doug Gentilcore - Senior VP & Head of DANYELZA Business Unit Natalie Tucker - Radiopharmaceutical Business Unit Head Peter Pfreundschuh - CFO Conference Call Participants Alec Stranahan - Bank of America Michael Wolf - M...
Neutral
GlobeNewsWire
29 days ago
Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZA Cash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 milli...
Neutral
GlobeNewsWire
about one month ago
Naxitamab demonstrated clinically meaningful efficacy with manageable safety in patients with relapsed/refractory high-risk neuroblastoma and residual disease in bone/bone marrow Naxitamab demonstrated clinically meaningful efficacy with manageable safety in patients with relapsed/refractory high-risk neuroblastoma and residual disease in bone/bone marrow
More Y-mAbs Therapeutics, Inc. News

Company Profile

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Head office United States
CEO Michael Rossi
Employees 107
Founded 2015
Website www.ymabs.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today